{
  "id": 10631328,
  "title": "Diätmittel: Novo kauft Lizenz für Abnehmpille von Hengrui",
  "url": "https://urgent.news/2026/09/29/diatmittel-novo-kauft-lizenz-fur-abnehmpille-von-hengrui",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-29T06:25:18.000Z",
  "source": {
    "name": "Handelsblatt",
    "slug": "handelsblatt",
    "url": "https://www.handelsblatt.com/unternehmen/industrie/diaetmittel-novo-kauft-lizenz-fuer-abnehmpille-von-hengrui/100258169.html"
  },
  "original_language": "de",
  "account": "Copenhagen - Novo Nordisk has acquired the license to an experimental weight-loss pill from Jiangsu Hengrui Pharmaceuticals for up to $2.6 billion. The experimental drug, in its early development stages, is seen by the company as a potential future hope beyond their best-selling medications, Ozempic and Wegovy. Novo initially pays $300 million for the rights to develop, manufacture, and market the drug globally, excluding mainland China, Hong Kong, Macau, and Taiwan. Hengrui can also earn revenue-based license fees. The drug HRS-1596 targets the GLP-1 and GIP receptors and is intended to be taken once a week. In China, it has been approved for clinical Phase 1 trials to treat obesity and diabetes. Currently available weight-loss pills, including Novo's products, require daily intake. Novo's research and development head, Martin Holst Lange, stated that the drug could \"set a new standard for convenience in this area.\"",
  "summary": "Der dänische Pharmakonzern setzt große Hoffnungen in ein experimentelles Abnehmmittel aus China. In einem Milliardendeal sichert sich der Konzern die weltweite Lizenz.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}